Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients

20252 citationsJournal Articlegold Open Access

Authors

Yvonne Füll · NewGen Therapeutics (United States)

Lara M. Schüssele · NewGen Therapeutics (United States)

Hazem Hamza · National Research Centre

Helen Hoffmann · NewGen Therapeutics (United States)

Martín W. Bauer · NewGen Therapeutics (United States)

Stephan Stenglein · NewGen Therapeutics (United States)

Oliver Pötz

Abstract

Unlike direct-acting antivirals, zapnometinib's dual effect highlights its therapeutic potential in the treatment of severe acute viral infections, with favorable antiviral and immunomodulatory properties.

Topics & Keywords

COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Long-Term Effects of COVID-19

Publication Details

Published in: Frontiers in Immunology

Volume 16, pp. 1631721-1631721

DOI: 10.3389/fimmu.2025.1631721

Field-Weighted Citation Impact: 2.91

Command Palette

Antiviral and immunomodulatory effect of zapnometinib in animal models and hospitalized COVID-19 patients

Authors

Abstract

Topics & Keywords

Publication Details